CME Group heads into its July 22 earnings with an interesting split: a fresh analyst upgrade sitting against a stock that has shed 12% in a month, with options positioning quietly turning more constructive.
The analyst angle is the standout this week. Rothschild & Co upgraded CME to Buy on June 11, lifting its target from $316 to $323 — a rare directional shift against a backdrop where most recent moves have been target cuts. Morgan Stanley and Barclays both trimmed targets after Q1 results in late April, with Morgan Stanley keeping Overweight at $353 (down from $362) and Barclays holding Equal-Weight at $316 (down from $343). The consensus remains Buy, with a mean target near $306 — roughly 17% above the current $261.60 close. JP Morgan is the clear outlier, running an Underweight with a $266 target, which at current prices leaves almost no implied upside in their model. The Street is not in agreement, but the direction of travel from most active names skews positive.
Positioning tells a similarly relaxed story for bears. Short interest is just 1.3% of free float — low enough that it earns no more than a line. It did rise about 11% over the past month, though it pulled back nearly 2% this week. Borrowing CME shares is essentially cost-free at 0.31%, down 25% on the week and more than 40% below month-ago levels. The lending pool is effectively unlimited — availability is at the top of its measured range, meaning new shorts face no friction whatsoever in sourcing stock. The ORTEX short score of 29.2 is well below any threshold that would suggest meaningful short-side pressure. What little bearish positioning exists is not building aggressively. Options tell a modestly different story: the put/call ratio of 0.98 has drifted below its 20-day average of 1.03, a near-one-standard-deviation move toward calls — suggesting options participants have actually become slightly less cautious than usual, even as the stock fell through May and into June.
The bull and bear cases have a structural quality to them. Bulls point to Q1 revenue of $1.649 billion, up 8.1% year-on-year, driven by 14.5% market data growth — a segment that is largely rate-cycle-agnostic. CME's average daily volume has compounded above 7% annually from 2016 to 2024, and the company has raised its quarterly dividend consistently for over 14 years. Bears counter that rate-cutting expectations weigh on the more cyclical futures volumes, and full-year guidance implies roughly 5.4% revenue growth, trailing the 6% consensus. Competitive pressure from FMX in interest rate futures remains a watch item. On valuation, the price-to-earnings ratio has compressed nearly 15% in 30 days to around 20.8x, and EV/EBITDA has eased to 18.3x — the multiple is no longer stretched, though value factor scores rank in the bottom quartile of the universe, reflecting a stock that remains expensive relative to its asset base. The dividend yield score (97th percentile) and analyst recommendation differential (99th percentile) are the standout factor reads.
Institutional ownership is concentrated and stable. BlackRock holds 8.7% of shares, adding about 372,000 shares in the most recent filing period. Capital Research added over 1.3 million shares. Morgan Stanley's position grew by nearly 1.5 million shares. These are index-level flows at the top, but the direction is incrementally supportive. On the insider side, CEO Terrence Duffy sold a combined $10.4 million of stock in mid-May at prices around $298-$305 — well above the current $261.60. Those sales look like scheduled disposals rather than conviction signals, but the price gap between his exit levels and today's close is notable context for how far the stock has moved.
Among the closest exchange-sector peers, CBOE stands out — it dropped 9.4% on Monday alone and is down 8.7% on the week, a sharp divergence from CME's 2.2% weekly gain. TW and MKTX both had solid weeks, up 2.4% and 7.1% respectively. ICE was flat. CME's relative outperformance versus CBOE this week is worth watching, given the two names typically carry a 57% return correlation — the gap either closes or signals a genuine divergence in business mix sensitivity.
The next focal point is the July 22 earnings release. Recent prints have been benign on reaction: the stock moved just 0.4% the day after Q1 results in April, and the most recent event in June produced a 4.7% one-day gain. With the multiple compressed and the Rothschild upgrade still fresh, how management frames the rate-environment outlook for the back half of the year is what will determine whether the discount to analyst targets begins to close.
See the live data behind this article on ORTEX.
Open CME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
